Amarin Pharma, FDA Talk Settlement Of Off-Label Lawsuit After Injunction

(August 31, 2015, 12:45 PM EDT) -- NEW YORK — Amarin Pharma Inc. and the Food and Drug Administration are exploring the possibility of settling Amarin’s off-label speech lawsuit, counsel for the drug company told a New York federal judge on Aug. 28 (Amarin Pharma, Inc., v. United States Food & Drug Administration, et al., No. 15-3588, S.D. N.Y.).

(Letter available. Document #28-150903-019X.)

In a letter to U.S. Judge Paul A. Engelmayer of the Southern District of New York, Floyd Abrams of Cahill, Gordon & Reindel in New York says that pursuant to...
To view the full article, register now.